Brainomix has announced its involvement in a new study sponsored by the University of Liverpool (Liverpool, UK) focused on post-stroke atrial fibrillation (AF). Sites with existing clinical deployments of Brainomix’s e-Stroke platform will utilise the artificial intelligence (AI) system to collect real-time imaging data and securely transfer them to the central investigators.
The Liverpool-Huawei Stroke Study aims to determine the clinical effectiveness, cost effectiveness and acceptability of Huawei Smartwear to detect AF in patients following an acute ischaemic stroke. Ultimately, a Brainomix press release states, the aim is to improve detection of AF to initiate earlier treatment and reduce risk of recurrent stroke in populations post-stroke.
Chief investigator Gregory Lip (Liverpool Centre for Cardiovascular Science, Liverpool, UK) said: “We are delighted by this collaboration with Brainomix, which enhances our growing research portfolio into stroke and atrial fibrillation research, and would help inform clinical practice and improve our care and management of these patients.”
George Harston, chief medical and innovation officer at Brainomix, added: “We are pleased to be involved in the Liverpool-Huawei Stroke Study, where our e-Stroke platform can provide trial investigators with high-quality, prospectively processed descriptive baseline imaging data.”
